<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26735600</article-id><article-id pub-id-type="pmc">4690658</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20150055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Adjunctive Hyperbaric Oxygen Therapy or Alone Antibiotherapy?
Methicillin Resistant <italic>Staphylococcus aureus</italic> Mediastinitis in a
Rat Model</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kurt</surname><given-names>Tolga</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Vural</surname><given-names>Ahmet</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Temiz</surname><given-names>Ahmet</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ozbudak</surname><given-names>Ersan</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yener</surname><given-names>Ali Umit</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sacar</surname><given-names>Suzan</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sacar</surname><given-names>Mustafa</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Cardiovascular Surgery, Canakkale Onsekiz Mart
University, School of Medicine, Canakkale, Turkey.</aff><aff id="aff2"><label>2</label>Department of Microbiology, Canakkale Onsekiz Mart University,
School of Medicine, Canakkale, Turkey.</aff><aff id="aff3"><label>3</label>Department of Cardiology, Canakkale Onsekiz Mart University, School
of Medicine, Canakkale, Turkey.</aff><aff id="aff4"><label>4</label>Department of Cardiovascular Surgery, Kocaeli University, School of
Medicine, Kocaeli, Turkey</aff><aff id="aff5"><label>5</label>Department of Infectious Disease and Clinical Microbiology,
Canakkale Onsekiz Mart University, Canakkale, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Tolga Kurt, School of Medicine, Canakkale
Onsekiz Mart University Department of Cardiovasculary Surgery Research and
Training Hospital, Sahil yolu street, n&#x000ba; 5, 17110, Kepez Canakkale
-Turkey. E-mail: <email>drtolgakurt17@gmail.com</email></corresp><fn fn-type="COI-statement"><p>Conflict of interest: Authors declare that there are no conflicts of
interest. </p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2015</year></pub-date><volume>30</volume><issue>5</issue><fpage>538</fpage><lpage>543</lpage><history><date date-type="received"><day>22</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>02</day><month>8</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License</license-p></license></permissions><abstract><sec><title>OBJECTIVE</title><p> In the post-sternotomy mediastinitis patients, <italic>Staphylococcus
aureus</italic> is the pathogenic microorganism encountered most often.
In our study, we aimed to determine the efficacy of antibiotic treatment
with vancomycin and tigecycline, alone or in combination with hyperbaric
oxygen treatment, on bacterial elimination in experimental S. aureus
mediastinitis.</p></sec><sec><title>METHODS</title><p> Forty-nine adult female Wistar rats were used. They were randomly divided
into seven groups, as follows: non-contaminated, contaminated control,
vancomycin, tigecycline, hyperbaric oxygen, hyperbaric oxygen + vancomycin
and hyperbaric oxygen + tigecycline. The vancomycin rat group received 10
mg/kg/day of vancomycin twice a day through intramuscular injection. The
tigecycline group rats received 7 mg/kg/day of tigecycline twice a day
through intraperitoneal injection. The hyperbaric oxygen group underwent 90
min sessions of 100% oxygen at 2.5 atm pressure. Treatment continued for 7
days. Twelve hours after the end of treatment, tissue samples were obtained
from the upper part of the sternum for bacterial count assessment.</p></sec><sec><title>RESULTS</title><p> When the quantitative bacterial counts of the untreated contaminated group
were compared with those of the treated groups, a significant decrease was
observed. However, comparing the antibiotic groups with the same antibiotic
combined with hyperbaric oxygen, there was a significant reduction in
microorganisms identified (<italic>P</italic>&#x0003c;0.05). Comparing hyperbaric
oxygen used alone with the vancomycin and tigecycline groups, it was seen
that the effect was not significant (<italic>P</italic>&#x0003c;0.05).</p></sec><sec><title>CONCLUSION</title><p> We believe that the combination of hyperbaric oxygen with antibiotics had a
significant effect on mediastinitis resulting from methicillin-resistant
<italic>Staphylococcus aureus</italic>. Methicillin-resistant
<italic>Staphylococcus aureus</italic> mediastinitis can be treated
without requiring a multidrug combination, thereby reducing the medication
dose and concomitantly decreasing the side effects.</p></sec></abstract><kwd-group><kwd>Mediastinitis</kwd><kwd>Hyperbaric Oxygenation</kwd><kwd>Vancomycin</kwd></kwd-group></article-meta></front><body><table-wrap id="t2" orientation="portrait" position="float"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th colspan="2" align="left" rowspan="1">
<bold>Abbreviations, acronyms &#x00026; symbols</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">HBO</td><td rowspan="1" colspan="1">= Hyperbaric oxygen</td></tr><tr><td rowspan="1" colspan="1">MIC</td><td rowspan="1" colspan="1">= Minimum inhibitory concentrations</td></tr><tr><td rowspan="1" colspan="1">MRSA</td><td rowspan="1" colspan="1">= Methicillin-resistant <italic>Staphylococcus aureus</italic></td></tr><tr><td rowspan="1" colspan="1">PBS</td><td rowspan="1" colspan="1">= Phosphate-buffered saline</td></tr><tr><td rowspan="1" colspan="1">SD</td><td rowspan="1" colspan="1">= Standard deviation</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>While mediastinitis developing on the median sternotomy incision after heart surgery
is rarely seen (0.5-8%), it is a complication with serious results the majority of
the time<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Hospital
stays related to mediastinitis increase hospital costs<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. It frequently occurs due to the endogenous flora of
the patient inoculating the surgical mediastinal cavity. After cardiac surgery with
median sternotomy, the most frequently observed pathogen is methicillin-resistant
<italic>Staphylococcus aureus</italic> (MRSA), which is also the bacterium
isolated in most blood cultures<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>After diagnosis of mediastinitis, in addition to serious antibiotic treatment,
surgical interventions such as primary closure after sternum debridement using
vancomycine paste instead of bone vax, closing with a muscle flap after total
removal of the sternum using skeletonised left internal thoracic artery and closing
the skin completely for closed drainage may be used<sup>[<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Due to the bactericidal properties of vancomycin on
methicillin-resistant staphylococcal infections, systemic vancomycin is the most
frequently chosen antibiotic for severe infections like mediastinitis after surgery
linked to MRSA<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.
However, side effects such as renal failure and hearing loss may be observed to be
linked to vancomycin use<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. To protect against these unwanted side effects there
is a need to use additional treatments. Adjuvant treatments like hyperbaric oxygen
(HBO) treatment are required, but there are insufficient data n this topic in the
current literature<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Tigecycline is a broad-spectrum glycylcycline effective against Gram-positive and
Gram-negative pathogens in soft tissue infections. Between 2004 and 2009, no
resistance to tigecycline was observed in soft tissue infections with MRSA, and all
the minimum inhibitory concentrations (MIC) were at or below susceptibility break
points<sup>[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p>Studies comparing new antibiotics like tigecycline with vancomycin have shown that
tigecycline is more effective against MRSA<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. An experimental rat model found that
tigecycline was significantly superior to vancomycin in this
application<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. HBO has become a focus of interest for mediastinitis
treatment in recent years; however, the patient numbers in both experimental and
prospective randomised studies are insufficient<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>The main aim of our study was to compare the efficacy of HBO alone and combined with
tigecycline and vancomycin in an experimental model of mediastinitis. In addition,
we aimed to compare the proven therapeutic effectiveness of vancomycin against MRSA
with the newer antibiotic tigecycline in an experimental mediastinitis model.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The study was performed at the Canakkale Onsekiz Mart University Experimental
Research Application and Research Centre. It was approved by the Canakkale Onsekiz
Mart University Animal Research Ethics Committee, Canakkale, Turkey. All animals
received human care in compliance with the principles of laboratory animal care
developed by the National Academy of Sciences<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. During the study, the animals were housed
in Canakkale Onsekiz Mart University Experimental Research Application and Research
Centre under veterinary control in rooms with a temperature of 25&#x000ba;C and
humidity of 52%, and given free access to standard feed and water.</p><sec><title>Organisms and susceptibility testing</title><p>This study used the ATCC 43300 strain of MRSA. The antibiotic susceptibility was
assessed with a Vitek 2 (BioM&#x000e9;rieux, Marcy l'Etoile, France) in the
Microbiology Laboratory of Canakkale Onsekiz Mart University.</p></sec><sec><title>In vivo rat model and drugs</title><p>This study used 49 female adult Wistar rats weighting 250-300 g, with each group
comprising 7 rats. The rats were randomly divided into seven groups, as follows:
uncontaminated control (group 1), contaminated control (group 2), vancomycin
(group 3), tigecycline (group 4), HBO (group 5), vancomycin+HBO (group 6) and
tigecycline+HBO (group 7). To anaesthetise the rats, ketamine hydrochloride (90
mg/kg of body weight; Pfizer, Luleburgaz, Turkey) and xylazine hydrochloride (3
mg/kg of body weight; Bayer AG, Leverkusen, Germany) were used. Each animal was
laid securely in supine position for the operation. After, the chest wall was
cleaned with 10% povidone-iodine, a sterile towel was used to cover the sternum
(<xref ref-type="fig" rid="f1">Figure 1</xref>), and then a central line
skin incision was completed. Both major pectoral muscles were divided along the
central line and the sternal bone was exposed well. The mid-sternal incision was
completed using a no. 15 blade; after, haemostasis was provided by sterile
sponges, the mediastinum was entered behind the sternum and a pocket was formed.
In the sham group rats, non-contaminated sterile physiological serum was
injected into the mediasternal pocket. In all other groups a concentration of
2x10<sup>7</sup> colony-forming units (CFU)/ml of MRSA strain ATCC 43300 in
1 ml of physiological serum solution was injected into the mediastinum with an
insulin injector and the mediastinum was filled with fluid. Later, the sternum
and subdermis were sutured with 5/0 polypropylene suture material.</p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Mediastinal appearance before sternotomy.</p></caption><graphic xlink:href="rbccv-30-05-0538-g01"/></fig><p>After the surgical procedure, the rats were placed in cages and monitored for
hyperaemia, oedema, fever and purulent discharge for seven days. During this
time, the rats had free access to standard feed and water. Treatment began 2
days later. In groups 1 and 2, no medication was administered. Postoperatively,
in Groups 3, 4, 6 and 7, antibiotic treatment was given twice a day for 7 days.
In Groups 5, 6 and 7, HBO with 100% oxygen at a pressure of 2.5 atm was
administered once a day for 7 days (<xref ref-type="table" rid="t1">Table
1</xref>). To identify the microbial load in rats in the non-contaminated
and contaminated control groups, at the start of treatment, the non-contaminated
animals were sacrificed and equal size thin sections of the upper sternum were
removed (<xref ref-type="fig" rid="f2">Figure 2</xref>). The rats in all of the
other groups had sternotomy applied 12 h after the end of the 7 day treatment.
Equal-sized tissue pieces and the upper section of the contaminated part of the
sternum were removed by sternotomy under aseptic conditions. Later, the animals
were given a high dose of anaesthetic and sacrificed.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>The results of experimental rat mediastinitis after treatment.</p></caption><table frame="hsides" rules="all"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th align="center" rowspan="1" colspan="1">Groups</th><th align="center" rowspan="1" colspan="1">Therapy</th><th align="center" rowspan="1" colspan="1">Number of culture negative/ total</th><th align="center" rowspan="1" colspan="1">Bacterial count: Mean&#x000b1;S.D.
log<sub>10</sub>CFU/g</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Group 1 n=7</td><td align="center" rowspan="1" colspan="1">No therapy (Uncontaminated)</td><td align="center" rowspan="1" colspan="1">10/10</td><td align="center" rowspan="1" colspan="1">0.0</td></tr><tr><td align="center" rowspan="1" colspan="1">Group 2 n=7</td><td align="center" rowspan="1" colspan="1">No therapy (Contaminated)</td><td align="center" rowspan="1" colspan="1">0/10</td><td align="center" rowspan="1" colspan="1">3.96&#x000b1;0.56</td></tr><tr><td align="center" rowspan="1" colspan="1">Group 3 n=7</td><td align="center" rowspan="1" colspan="1">Vancomycin</td><td align="center" rowspan="1" colspan="1">0/10</td><td align="center" rowspan="1" colspan="1">1.90&#x000b1;0.27</td></tr><tr><td align="center" rowspan="1" colspan="1">Group 4 n=7</td><td align="center" rowspan="1" colspan="1">Tigesiklin</td><td align="center" rowspan="1" colspan="1">0/10</td><td align="center" rowspan="1" colspan="1">2.05&#x000b1;0.32</td></tr><tr><td align="center" rowspan="1" colspan="1">Group 5 n=7</td><td align="center" rowspan="1" colspan="1">HBO</td><td align="center" rowspan="1" colspan="1">0/10</td><td align="center" rowspan="1" colspan="1">3.11&#x000b1;0.54</td></tr><tr><td align="center" rowspan="1" colspan="1">Group 6 n=7</td><td align="center" rowspan="1" colspan="1">Vancomycin+HBO</td><td align="center" rowspan="1" colspan="1">0/10</td><td align="center" rowspan="1" colspan="1">1.52&#x000b1;0.95</td></tr><tr><td align="center" rowspan="1" colspan="1">Group 7 n=7</td><td align="center" rowspan="1" colspan="1">Tigesiklin+HBO</td><td align="center" rowspan="1" colspan="1">0/10</td><td align="center" rowspan="1" colspan="1">1.79&#x000b1;0.98</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>Mean&#x000b1;S.D. log<sub>10</sub> CFU/g</p></fn></table-wrap-foot></table-wrap><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Removing of the upper sternum.</p></caption><graphic xlink:href="rbccv-30-05-0538-g02"/></fig></sec><sec><title>Treatment protocols</title><p>Group I (sham group; n=7): Uncontaminated control group, no contamination or
antibiotic therapy.</p><p>Group II (control group; n=7): Untreated contaminated control group, local
contamination with MRSA, no antibiotic therapy.</p><p>Group III (vancomycin group; n=7): Vancomycin (Edicine, Sandoz, Istanbul, Turkey)
intramuscular injections at 10 mg/kg/ day, twice a day for 7 days.</p><p>Group IV (tigecycline group; n=7): Tigecycline (Tygacil, Wyeth Pharmaceuticals,
Havant, UK) intraperitoneal injections at 7 mg/kg/day, twice a day for 7
days.</p><p>Group V (HBO group; n=7): HBO with 100% oxygen at a pressure of 2.5 atm for 90
min, once a day for 7 days.</p><p>Group VI (vancomycin + HBO group; n=7): Vancomycin intramuscular injections at 10
mg/kg/day, twice a day for 7 days, and HBO with 100% oxygen at a pressure of 2.5
atm once a day.</p><p>Group VII (tigecycline + HBO group; n=7): Tigecycline intraperitoneal injections
at 7 mg/kg/day, twice a day for 7 days, and HBO with 100% oxygen at a pressure
of 2.5 atm once a day.</p></sec><sec><title>Assessment of the infection</title><p>The explanted sternal upper portion and surrounding tissue samples were placed in
sterile tubes and washed in sterile saline solution. Following this, they were
placed in tubes containing 10 ml of phosphate-buffered saline (PBS) solution,
and vortexed for 1 min to remove the adhering bacteria from the tissue and
sternum. Quantification of viable bacteria was performed by culturing serial
10-fold dilutions (0.1 ml) of the bacterial suspension on blood agar plates. All
plates were incubated at 37&#x000ba;C for 48 h and evaluated for the presence of
MRSA. The organisms were quantitated by counting the number of CFU/g per tissue.
The results were converted to log form.</p></sec><sec><title>Statistical analysis</title><p>Quantitative culture results are presented as arithmetic mean&#x000b1;standard
deviation (SD) CFU/ml. Differences among the groups were evaluated using
Kruskal-Wallis analysis and multiple comparisons between the groups were
performed using the Mann-Whitney test. Differences were considered statistically
significant when <italic>P</italic>&#x0003c;0.05. Data were analysed by statistical
software (SPSS for Windows 17.0; SPSS, Chicago, IL).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>In this study, we aimed to assess the efficacy of vancomycin, which has been proven
for the treatment of mediastinitis, in comparison with the relatively newly used
tigecycline, HBO and combinations of these. In all contaminated rats, macroscopic
mediastinitis findings were observed (tissue oedema). Especially in the untreated
contaminated group, advanced-degree infected tissues with purulent fibrin adhesions
were present. With the exception of group 1, comprising non-contaminated rats which
were not given antibiotherapy, macroscopic mediastinitis findings in the groups were
compared. The culture-negative rates and bacterial counts linked to mediastinitis in
each group are shown in <xref ref-type="table" rid="t1">Table 1</xref>. The mean
growth sizes of microorganisms in the mediastinal areas within the sternum were
compared. When the quantitative bacterial counts in the mediastinal region within
the sternum in the contaminated non-treated group (group 2) were compared with the
treated groups (group 3-7), a significant reduction was observed
(<italic>P</italic>&#x0003c;0.05). Comparing groups with vancomycin and tigecycline
administered as prophylactics, there was no statistically significant difference
observed (<italic>P</italic>&#x0003e;0.05). However, comparing the antibiotic groups with
the same antibiotic combined with HBO, there was a significant reduction in the
number of microorganisms (<italic>P</italic>&#x0003c;0.05). In addition, when the
vancomycin+HBO (group 6) and tigecycline+HBO (group 7) were compared, there was a
significant reduction in the amount of microorganisms in the group treated with
combined vancomycin (<italic>P</italic>&#x0003c;0.05).</p><p>Comparing the use of HBO alone with the untreated contaminated group, a significant
reduction in bacteria counts was observed (<italic>P</italic>&#x0003c;0.05); however,
comparing HBO alone with the vancomycin and tigecycline groups, the effect was
observed not to be significant (<italic>P</italic>&#x0003e;0.05).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this experimental mediastinitis model, we aimed to compare tigecycline with
vancomycin, which is classically used to treat mediastinitis linked to MRSA. In
addition, we aimed to compare the treatment efficacy of both antibiotics combined
with HBO. We proved that there was no statistical superiority of either antibiotic
when used alone.</p><p>In this study, we used previously applied experimental rat mediastinitis
models<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. When the literature was examined, we found several
animal models using tigecycline, vancomycin and HBO against MRSA, so we aimed to use
these antibiotics and HBO. However, we did not discover any rat model involving the
combined use of tigecycline and HBO<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r22" ref-type="bibr">22</xref>]</sup>. Tigecycline was first derived from minocycline, and is
a broad spectrum antibiotic of the glycylcycline class with broad in vitro
activity<sup>[<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r24" ref-type="bibr">24</xref>]</sup>.</p><p>There is no requirement to regulate the dose of tigecycline for patients with renal
failure or even those with mild to moderate hepatic dysfunction; moreover, it is not
induced or inhibited by cytochrome p450<sup>[<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r25" ref-type="bibr">25</xref>]</sup>. In addition, studies of medication interactions have
shown that when tigecycline is used with medications like warfarin and digoxin, no
side effects were observed in healthy individuals<sup>[<xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref>]</sup>. The most frequently observed side effects are mild to
moderate nausea and vomiting in the early stages, mainly the first 1-2
days<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>.</p><p>Tigecycline has been used successfully in the treatment of many severe and mortally
progressing types of mediastinitis, such as <italic>Mycobacterium chelonae</italic>,
pan-resistant <italic>Acinetobacter baumannii</italic> mediastinitis and
multidrug-resistant <italic>Klebsiella pneumoniae</italic>
mediastinitis<sup>[<xref rid="r29" ref-type="bibr">29</xref>-<xref rid="r31" ref-type="bibr">31</xref>]</sup>.</p><p>Vancomycin is an antibiotic frequently chosen for the treatment of severe MRSA
infections like mediastinitis. As this has a slow killing effect on glycopeptide
bacteria, it should be used for treatment of long-term diseases and this may cause a
risk of severe kidney failure for patients<sup>[<xref rid="r32" ref-type="bibr">32</xref>-<xref rid="r34" ref-type="bibr">34</xref>]</sup>. Although vancomycin is not routinely recommended for
use in cardiac surgery, it is important to use it in patients with an increased risk
or cases with a high incidence of MRSA<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup>. However, there has been no study on the role of
tigecycline in a rat model or in combination with HBO.</p><p>Another aim of our study was to compare the efficacy of HBO combined with antibiotic
treatment or used alone for MRSA mediastinitis. HBO therapy involves the treatment
of patients with 100% oxygen at higher than atmospheric pressure within a hyperbaric
chamber<sup>[<xref rid="r36" ref-type="bibr">36</xref>]</sup>.
HBO causes increased dissolved oxygen levels in blood; this in turn causes hyperoxia
in tissues. It restores the bactericidal capacity of leukocytes in hypoxic wounds by
increasing tissue oxygen tensions<sup>[<xref rid="r37" ref-type="bibr">37</xref>]</sup>. Moreover, it has been used to treat difficult
cases for many years. Although the effective mechanism of HBO is not fully
understood, it has been observed to activate many mechanisms, including collagen
synthesis<sup>[<xref rid="r38" ref-type="bibr">38</xref>]</sup>, accelerated macrophage infiltration<sup>[<xref rid="r39" ref-type="bibr">39</xref>]</sup>, fibroblast
proliferation<sup>[<xref rid="r40" ref-type="bibr">40</xref>,<xref rid="r41" ref-type="bibr">41</xref>]</sup>, growth factor proliferation<sup>[<xref rid="r42" ref-type="bibr">42</xref>,<xref rid="r43" ref-type="bibr">43</xref>]</sup>, modulation of hypoxia-inducible factor 1
alpha<sup>[<xref rid="r44" ref-type="bibr">44</xref>]</sup>,
improved antibactericidal capacity<sup>[<xref rid="r45" ref-type="bibr">45</xref>]</sup>, bacteriostatic effects<sup>[<xref rid="r46" ref-type="bibr">46</xref>,<xref rid="r47" ref-type="bibr">47</xref>]</sup> and stimulation of
angiogenesis<sup>[<xref rid="r48" ref-type="bibr">48</xref>]</sup>. In this study, when the use of HBO alone was compared
with the untreated group with MRSA mediastinitis, a reduction in the number of
bacteria was found; however, when HBO alone was compared with vancomycin and
tigecycline, the effect was not observed to be significant.</p><p>HBO (100% oxygen once per day for 90-120 min at 2-3 atm) can generally be combined
with antibiotics like penicillins, beta-lactamase inhibitors, cephalosporins,
aztreonam, imipenem, vancomycin, clindamycin, rifampin, aminoglycosides,
fluoroquinolones, trimethoprim/sulphamethoxazole, metronidazole, teicoplanin,
quinupristin and dalfopristin, and is used to treat osteomyelitis. Thus, the
efficacy of an antibiotic is increased in hypoxic tissues<sup>[<xref rid="r49" ref-type="bibr">49</xref>]</sup>. It has been observed that
HBO increases the effectiveness of debridement and antibiotic treatment. Topuz et
al.<sup>[<xref rid="r50" ref-type="bibr">50</xref>]</sup>
observed heightened efficacy when HBO was combined with antibiotics and surgery for
spinal tuberculosis patients.</p><p>In our study, similar to other research using HBO and combinations of a classic and
new antibiotic like vancomycin and teicoplanin, we researched the efficacy of these
treatments in rats with MRSA mediastinitis. While HBO alone resulted in a
significant drop in the number of bacteria, its combination with either antibiotic
significantly increased the efficacy of the medication.</p><p>When this study is evaluated, there are some limitations to consider. The pathogenic
bacteria were directly inoculated to the sternal and mediasternal layers, and this
situation is not appropriate for clinical comparison. For ethical reasons, the
treatment continued for 7 days, but longer duration of treatment may produce better
results. For technical reasons, we did not obtain sufficient data on systemic
infection (direct histological examination, white blood cells). Moreover, we did not
obtain sufficient data on the serum antibiotic concentrations. In spite of these
limitations, this is the only study to compare the effects of HBO with new
generation antibiotics like tigecycline in the in vivo environment.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>We conclude that the combination of HBO with antibiotics shows a significant effect
on MRSA mediastinitis. HBO can also reinforce antibacterial therapy and speed up
healing. MRSA mediastinitis can be treated without requiring multidrug combinations,
thereby decreasing the required dose of medication, and as a result, reducing its
side effects. In the future, ethical permission for human studies will determine the
efficacy of HBO in the treatment of MRSA mediastinitis.</p><table-wrap id="t3" orientation="portrait" position="float"><table frame="hsides" rules="groups"><thead><tr style="border-bottom-style:solid;border-top-style:solid"><th colspan="2" align="left" rowspan="1">
<bold>Authors' roles &#x00026; responsibilities</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">TK</td><td rowspan="1" colspan="1">Final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">AV</td><td rowspan="1" colspan="1">Study conception and design; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">AT</td><td rowspan="1" colspan="1">Manuscript writing and critical review of its content; final
manuscript approval</td></tr><tr><td rowspan="1" colspan="1">EO</td><td rowspan="1" colspan="1">Analysis/interpretation of data; statistical analysis; final
manuscript approval; manuscript writing or critical review of its
content</td></tr><tr><td rowspan="1" colspan="1">AUY</td><td rowspan="1" colspan="1">Conduct of operations/experiments; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">SS</td><td rowspan="1" colspan="1">Manuscript writing and critical review of its contents; final
manuscript approval</td></tr><tr><td rowspan="1" colspan="1">MS</td><td rowspan="1" colspan="1">Study conception and design; final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Department of Cardiovascular Surgery, Canakkale
Onsekiz Mart University, School of Medicine Canakkale, Turkey.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milano</surname><given-names>CA</given-names></name><name><surname>Kesler</surname><given-names>K</given-names></name><name><surname>Archibald</surname><given-names>N</given-names></name><name><surname>Sexton</surname><given-names>DJ</given-names></name><name><surname>Jones</surname><given-names>RH</given-names></name></person-group><article-title>Mediastinitis after coronary artery bypass graft surgery. Risk
factors and long-term survival</article-title><source>Circulation</source><year>1995</year><volume>92</volume><issue>8</issue><fpage>2245</fpage><lpage>2251</lpage><pub-id pub-id-type="pmid">7554208</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loop</surname><given-names>FD</given-names></name><name><surname>Lytle</surname><given-names>BW</given-names></name><name><surname>Cosgrove</surname><given-names>DM</given-names></name><name><surname>Mahfood</surname><given-names>S</given-names></name><name><surname>McHenry</surname><given-names>MC</given-names></name><name><surname>Goormastic</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sternal wound complications after isolated coronary artery bypass
grafting: early and late mortality, morbidity, and cost of
care</article-title><source>Ann Thorac Surg</source><year>1990</year><volume>49</volume><fpage>179</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">2306138</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappstein</surname><given-names>I</given-names></name><name><surname>Schulgen</surname><given-names>G</given-names></name><name><surname>Fraedrich</surname><given-names>G</given-names></name><name><surname>Schlosser</surname><given-names>V</given-names></name><name><surname>Schumacher</surname><given-names>M</given-names></name><name><surname>Daschner</surname><given-names>FD</given-names></name></person-group><article-title>Added hospital stay due to wound infections following cardiac
surgery</article-title><source>Thorac Cardiovasc Surg</source><year>1992</year><volume>40</volume><issue>3</issue><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">1412382</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;</surname><given-names>MP</given-names></name><name><surname>Silva</surname><given-names>DO</given-names></name><name><surname>Lima</surname><given-names>EN</given-names></name><name><surname>Lima</surname><given-names>RC</given-names></name><name><surname>Silva</surname><given-names>FP</given-names></name><name><surname>Rueda</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Postoperative mediastinitis in cardiovascular surgery
postoperations. Analysis of 1038 consecutive surgeries</article-title><source>Rev Bras Cir Cardiovasc</source><year>2010</year><volume>25</volume><issue>1</issue><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">20563463</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardlund</surname><given-names>B</given-names></name><name><surname>Bitkover</surname><given-names>CY</given-names></name><name><surname>Vaage</surname><given-names>J</given-names></name></person-group><article-title>Postoperative mediastinitis in cardiac surgery: microbiology and
pathogenesis</article-title><source>Eur J Cardiothorac Surg</source><year>2002</year><volume>21</volume><issue>5</issue><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">12062270</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arruda</surname><given-names>MV</given-names></name><name><surname>Braile</surname><given-names>DM</given-names></name><name><surname>Joaquim</surname><given-names>MR</given-names></name><name><surname>Suzuki</surname><given-names>FA</given-names></name><name><surname>Alves</surname><given-names>RH</given-names></name></person-group><article-title>The use of the vancomycin paste for sternal hemostasis and
mediastinitis prophylaxis</article-title><source>Rev Bras Cir Cardiovasc</source><year>2008</year><volume>23</volume><issue>1</issue><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">18719826</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;</surname><given-names>MP</given-names></name><name><surname>Soares</surname><given-names>EF</given-names></name><name><surname>Santos</surname><given-names>CA</given-names></name><name><surname>Figueiredo</surname><given-names>OJ</given-names></name><name><surname>Lima</surname><given-names>RO</given-names></name><name><surname>Escobar</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Skelotenized left internal thoracic artery is associated with
lower rates of mediastinitis in diabetic patients</article-title><source>Rev Bras Cir Cardiovasc</source><year>2011</year><volume>26</volume><issue>2</issue><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">21894407</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvat</surname><given-names>S</given-names></name><name><surname>Trouillet</surname><given-names>JL</given-names></name><name><surname>Nataf</surname><given-names>P</given-names></name><name><surname>Vuagnat</surname><given-names>A</given-names></name><name><surname>Chastre</surname><given-names>J</given-names></name><name><surname>Gibert</surname><given-names>C</given-names></name></person-group><article-title>Closed drainage using Redon catheters for local treatment of
poststernotomy mediastinitis</article-title><source>Ann Thorac Surg</source><year>1996</year><volume>61</volume><issue>1</issue><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">8561552</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>ME</given-names></name></person-group><chapter-title>Mediastinitis</chapter-title><person-group person-group-type="editor"><name><surname>Mandell</surname><given-names>GL</given-names></name><name><surname>Bennet</surname><given-names>JE</given-names></name><name><surname>Dolin</surname><given-names>R</given-names></name></person-group><source>Principles and practice of infectious diseases</source><edition>6th ed</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Elsevier Churchill Livingstone</publisher-name><year>2005</year><fpage>1070</fpage><lpage>1078</lpage></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traber</surname><given-names>PG</given-names></name><name><surname>Levine</surname><given-names>DP</given-names></name></person-group><article-title>Vancomycin ototoxicity in patient with normal renal
function</article-title><source>Ann Intern Med</source><year>1981</year><volume>95</volume><issue>4</issue><fpage>458</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">7283300</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turhan</surname><given-names>V</given-names></name><name><surname>Sacar</surname><given-names>S</given-names></name><name><surname>Uzun</surname><given-names>G</given-names></name><name><surname>Sacar</surname><given-names>M</given-names></name><name><surname>Yildiz</surname><given-names>S</given-names></name><name><surname>Ceran</surname><given-names>N</given-names></name><etal/></person-group><article-title>Hyperbaric oxygen as adjunctive therapy in experimental
mediastinitis</article-title><source>J Surg Res</source><year>2009</year><volume>155</volume><issue>1</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">19181335</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namdari</surname><given-names>H</given-names></name><name><surname>Tan</surname><given-names>T</given-names></name><name><surname>Dowzicky</surname><given-names>Y</given-names></name></person-group><article-title>Activity of tigecycline and comparators against skin and skin
structure pathogens: global results of the Tigecycline Evaluation and
Surveillance Trial, 20042009</article-title><source>Int J Infect Dis</source><year>2012</year><volume>16</volume><issue>1</issue><fpage>e60</fpage><lpage>e66</lpage><pub-id pub-id-type="pmid">22104303</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puzniak</surname><given-names>LA</given-names></name><name><surname>Quintana</surname><given-names>A</given-names></name><name><surname>Wible</surname><given-names>M</given-names></name><name><surname>Babinchak</surname><given-names>T</given-names></name><name><surname>McGovern</surname><given-names>PC</given-names></name></person-group><article-title>Methicillin-resistant Staphylococcus aureus infection
epidemiology and clinical response from tigecycline soft tissue infection
trials</article-title><source>Diagn Microbiol Infect Dis</source><year>2014</year><volume>79</volume><issue>2</issue><fpage>261</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">24725736</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarai</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><article-title>Recurrent challenges for clinicians: emergence of
methicillin-resistant Staphylococcus aureus, vancomycin resistance, and
current treatment options</article-title><source>J Lab Physicians</source><year>2013</year><volume>5</volume><issue>2</issue><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">24701097</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonopoulou</surname><given-names>A</given-names></name><name><surname>Tsaganos</surname><given-names>T</given-names></name><name><surname>Tzepi</surname><given-names>IM</given-names></name><name><surname>Giamarellou</surname><given-names>H</given-names></name><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name></person-group><article-title>Comparative efficacy of tigecycline VERSUS vancomycin in an
experimental model of soft tissue infection by methicillin-resistant
Staphylococcus aureus producing Panton-Valentine leukocidin</article-title><source>J Chemother</source><year>2015</year><volume>27</volume><issue>2</issue><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24548093</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egito</surname><given-names>JG</given-names></name><name><surname>Abboud</surname><given-names>CS</given-names></name><name><surname>Oliveira</surname><given-names>AP</given-names></name><name><surname>M&#x000e1;ximo</surname><given-names>CA</given-names></name><name><surname>Montenegro</surname><given-names>CM</given-names></name><name><surname>Amato</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Clinical evolution of mediastinitis in patients undergoing
adjuvant hyperbaric oxygen therapy after coronary artery bypass
surgery</article-title><source>Einstein</source><year>2013</year><volume>11</volume><issue>3</issue><fpage>345</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">24136762</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="book"><source>Institute of Laboratory Animal Resources National Research Council:
Guide for the care and use of laboratory animals</source><publisher-loc>Washington</publisher-loc><publisher-name>National Academy Press</publisher-name><year>1996</year></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ersoz</surname><given-names>G</given-names></name><name><surname>Aytacoglu</surname><given-names>BN</given-names></name><name><surname>Sucu</surname><given-names>N</given-names></name><name><surname>Tamer</surname><given-names>L</given-names></name><name><surname>Bayindir</surname><given-names>I</given-names></name><name><surname>Kose</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparison and evaluation of experimental mediastinitis models:
precolonized foreign body implants and bacterial suspension inoculation
seems promising</article-title><source>BMC Infect Dis</source><year>2006</year><volume>6</volume><fpage>76</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">16638144</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacar</surname><given-names>M</given-names></name><name><surname>Sacar</surname><given-names>S</given-names></name><name><surname>Kaleli</surname><given-names>I</given-names></name><name><surname>Cevahir</surname><given-names>N</given-names></name><name><surname>Teke</surname><given-names>Z</given-names></name><name><surname>Kavas</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Efficacy of linezolid in the treatment of mediastinitis due to
methicillinresistant Staphylococcus aureus: an experimental
study</article-title><source>Int J Infect Dis</source><year>2008</year><volume>12</volume><issue>4</issue><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">18162429</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oguz</surname><given-names>E</given-names></name><name><surname>Ekinci</surname><given-names>S</given-names></name><name><surname>Eroglu</surname><given-names>M</given-names></name><name><surname>Bilgic</surname><given-names>S</given-names></name><name><surname>Koca</surname><given-names>K</given-names></name><name><surname>Durusu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Evaluation and comparison of the effects of hyperbaric oxygen and
ozonized oxygen as adjuvant treatments in an experimental osteomyelitis
model</article-title><source>J Surg Res</source><year>2011</year><volume>171</volume><issue>1</issue><fpage>e61</fpage><lpage>e68</lpage><pub-id pub-id-type="pmid">21920551</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turhan</surname><given-names>V</given-names></name><name><surname>Sacar</surname><given-names>S</given-names></name><name><surname>Uzun</surname><given-names>G</given-names></name></person-group><article-title>Hyperbaric oxygen as adjunctive therapy in experimental
mediastinitis</article-title><source>J Surg Res</source><year>2009</year><volume>155</volume><issue>1</issue><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">19181335</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>AV</given-names></name><name><surname>Demir</surname><given-names>M</given-names></name><name><surname>Onem</surname><given-names>G</given-names></name><name><surname>Goksin</surname><given-names>I</given-names></name><name><surname>Baltalarli</surname><given-names>A</given-names></name><name><surname>Topkara</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Topical versus systemic vancomycin for deep sternal wound
infection caused by methicillin-resistant Staphylococcus aureus in a rodent
experimental model</article-title><source>Tex Heart Inst J</source><year>2006</year><volume>33</volume><issue>2</issue><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">16878608</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>LR</given-names></name></person-group><article-title>A review of tigecycline-the first glycylcycline</article-title><source>Int J Antimicrob Agents</source><year>2008</year><volume>32</volume><issue>Suppl 4</issue><fpage>S215</fpage><lpage>S222</lpage><pub-id pub-id-type="pmid">19134522</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livermore</surname><given-names>DM</given-names></name></person-group><article-title>Tigecycline: what is it, and where should it be
used?</article-title><source>J Antimicrob Chemother</source><year>2005</year><volume>56</volume><issue>4</issue><fpage>611</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">16120626</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacGowan</surname><given-names>AP</given-names></name></person-group><article-title>Tigecycline pharmacokinetic/pharmacodynamic
update</article-title><source>J Antimicrob Chemother</source><year>2008</year><volume>62</volume><issue>Suppl 1</issue><fpage>i11</fpage><lpage>i16</lpage><pub-id pub-id-type="pmid">18684702</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>JJ</given-names></name><name><surname>Harper</surname><given-names>DM</given-names></name><name><surname>Matschke</surname><given-names>K</given-names></name><name><surname>Speth</surname><given-names>JL</given-names></name><name><surname>Raible</surname><given-names>DG</given-names></name><name><surname>Fruncillo</surname><given-names>RJ</given-names></name></person-group><article-title>Absence of an interaction between tigecycline and digoxin in
healthy men</article-title><source>Pharmacotherapy</source><year>2007</year><volume>27</volume><issue>6</issue><fpage>835</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">17542766</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>JJ</given-names></name><name><surname>Raible</surname><given-names>DG</given-names></name><name><surname>Harper</surname><given-names>DM</given-names></name><name><surname>Matschke</surname><given-names>K</given-names></name><name><surname>Speth</surname><given-names>JL</given-names></name></person-group><article-title>Evaluation of a potential tigecycline warfarin drug
interaction</article-title><source>Pharmacotherapy</source><year>2008</year><volume>28</volume><issue>7</issue><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">18576904</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis-Grosse</surname><given-names>EJ</given-names></name><name><surname>Babinchak</surname><given-names>T</given-names></name><name><surname>Dartois</surname><given-names>N</given-names></name><name><surname>Rose</surname><given-names>G</given-names></name><name><surname>Loh</surname><given-names>E</given-names></name><collab>Tigecycline 300 cSSSI Study Group</collab><collab>Tigecycline 305 cSSSI Study Group</collab></person-group><article-title>The efficacy and safety of tigecycline in the treatment of skin
and skin-structure infections: results of 2 double-blind phase 3 comparison
studies with vancomycin-aztreonam</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41</volume><issue>Suppl 5</issue><fpage>S341</fpage><lpage>S353</lpage><pub-id pub-id-type="pmid">16080072</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unai</surname><given-names>S</given-names></name><name><surname>Miessau</surname><given-names>J</given-names></name><name><surname>Karbowski</surname><given-names>P</given-names></name><name><surname>Bajwa</surname><given-names>G</given-names></name><name><surname>Hirose</surname><given-names>H</given-names></name></person-group><article-title>Sternal wound infection caused by Mycobacterium
chelonae</article-title><source>J Card Surg</source><year>2013</year><volume>28</volume><issue>6</issue><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">23941599</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tek&#x000e7;e</surname><given-names>AY</given-names></name><name><surname>Erbay</surname><given-names>A</given-names></name><name><surname>&#x000c7;abadak</surname><given-names>H</given-names></name><name><surname>Yagci</surname><given-names>S</given-names></name><name><surname>Karabiber</surname><given-names>N</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name></person-group><article-title>Pan-resistant Acinetobacter baumannii mediastinitis treated
successfully with tigecycline: a case report</article-title><source>Surg Infect (Larchmt)</source><year>2011</year><volume>12</volume><issue>2</issue><fpage>141</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">21348768</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evagelopoulou</surname><given-names>P</given-names></name><name><surname>Myrianthefs</surname><given-names>P</given-names></name><name><surname>Markogiannakis</surname><given-names>A</given-names></name><name><surname>Baltopoulos</surname><given-names>G</given-names></name><name><surname>Tsakris</surname><given-names>A</given-names></name></person-group><article-title>Multidrug-resistant Klebsiella pneumoniae mediastinitis safely
and effectively treated with prolonged administration of
tigecycline</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><issue>12</issue><fpage>1932</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">18540810</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangin</surname><given-names>O</given-names></name><name><surname>Urien</surname><given-names>S</given-names></name><name><surname>Mainardi</surname><given-names>JL</given-names></name><name><surname>Fagon</surname><given-names>JY</given-names></name><name><surname>Faisy</surname><given-names>C</given-names></name></person-group><article-title>Vancomycin pharmacokinetic and pharmacodynamic models for
critically ill patients with post-sternotomy mediastinitis</article-title><source>Clin Pharmacokinet</source><year>2014</year><volume>53</volume><issue>9</issue><fpage>849</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">25117184</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contreiras</surname><given-names>C</given-names></name><name><surname>Legal</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>TT</given-names></name><name><surname>Thalakada</surname><given-names>R</given-names></name><name><surname>Shalansky</surname><given-names>S</given-names></name><name><surname>Ensom</surname><given-names>MH</given-names></name></person-group><article-title>Identification of risk factors for nephrotoxicity in patients
receiving extended-duration, high-trough vancomycin therapy</article-title><source>Can J Hosp Pharm</source><year>2014</year><volume>67</volume><issue>2</issue><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">24799722</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnea</surname><given-names>Y</given-names></name><name><surname>Navon-Venezia</surname><given-names>S</given-names></name><name><surname>Kuzmenko</surname><given-names>B</given-names></name><name><surname>Artzi</surname><given-names>N</given-names></name><name><surname>Carmeli</surname><given-names>Y</given-names></name></person-group><article-title>Ceftobiprole medocaril is an effective treatment against
methicillinresistant Staphylococcus aureus (MRSA) mediastinitis in a rat
model</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2014</year><volume>33</volume><issue>3</issue><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">24030718</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoe</surname><given-names>DS</given-names></name><name><surname>Mermel</surname><given-names>LA</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Arias</surname><given-names>KM</given-names></name><name><surname>Burstin</surname><given-names>H</given-names></name><name><surname>Calfee</surname><given-names>DP</given-names></name><etal/></person-group><article-title>A compendium of strategies to prevent healthcare-associated
infections in acute care hospitals</article-title><source>Infect Control Hosp Epidemiol</source><year>2008</year><volume>29</volume><issue>Suppl 1</issue><fpage>S12</fpage><lpage>S21</lpage><pub-id pub-id-type="pmid">18840084</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibbles</surname><given-names>PM</given-names></name><name><surname>Edelsberg</surname><given-names>JS</given-names></name></person-group><article-title>Hyperbaric-oxygen therapy</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><issue>25</issue><fpage>1642</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">8628361</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cimsit</surname><given-names>M</given-names></name><name><surname>Uzun</surname><given-names>G</given-names></name><name><surname>Yildiz</surname><given-names>S</given-names></name></person-group><article-title>Hyperbaric oxygen therapy as an anti-infective
agent</article-title><source>Expert Rev Anti Infect Ther</source><year>2009</year><volume>7</volume><issue>8</issue><fpage>1015</fpage><lpage>1026</lpage><pub-id pub-id-type="pmid">19803709</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>TK</given-names></name><name><surname>Pai</surname><given-names>MP</given-names></name></person-group><article-title>The effect of varying ambient oxygen tensions on wound metabolism
and collagen synthesis</article-title><source>Surg Gynecol Obstet</source><year>1972</year><volume>135</volume><issue>4</issue><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">5077722</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>N</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Tomioka</surname><given-names>T</given-names></name><name><surname>Deie</surname><given-names>M</given-names></name></person-group><article-title>Effects of hyperbaric oxygen at 1.25 atmospheres absolute with
normal air on macrophage number and infiltration during rat skeletal muscle
regeneration</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>12</issue><elocation-id/></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brismar</surname><given-names>K</given-names></name><name><surname>Lind</surname><given-names>F</given-names></name><name><surname>Kratz</surname><given-names>G</given-names></name></person-group><article-title>Dose-dependent hyperbaric oxygen stimulation of human fibroblast
proliferation</article-title><source>Wound Repair Regen</source><year>1997</year><volume>5</volume><issue>2</issue><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">16984424</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>TS</given-names></name><name><surname>Gorti</surname><given-names>GK</given-names></name><name><surname>Quan</surname><given-names>SY</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name><name><surname>Koch</surname><given-names>RJ</given-names></name></person-group><article-title>Effect of hyperbaric oxygen on the growth factor profile of
fibroblasts</article-title><source>Arch Facial Plast Surg</source><year>2004</year><volume>6</volume><issue>1</issue><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">14732642</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>LL</given-names></name><name><surname>Davidson</surname><given-names>JD</given-names></name><name><surname>Wee</surname><given-names>SC</given-names></name><name><surname>Roth</surname><given-names>SI</given-names></name><name><surname>Mustoe</surname><given-names>TA</given-names></name></person-group><article-title>Effect of hyperbaric oxygen and growth factors on rabbit ear
ischemic ulcers</article-title><source>Arch Surg</source><year>1994</year><volume>129</volume><issue>10</issue><fpage>1043</fpage><lpage>1049</lpage><pub-id pub-id-type="pmid">7944933</pub-id></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheikh</surname><given-names>AY</given-names></name><name><surname>Gibson</surname><given-names>JJ</given-names></name><name><surname>Rollins</surname><given-names>MD</given-names></name><name><surname>Hopf</surname><given-names>HW</given-names></name><name><surname>Hussain</surname><given-names>Z</given-names></name><name><surname>Hunt</surname><given-names>TK</given-names></name></person-group><article-title>Effect of hyperoxia on vascular endothelial growth factor levels
in a wound model</article-title><source>Arch Surg</source><year>2000</year><volume>135</volume><issue>11</issue><fpage>1293</fpage><lpage>1297</lpage><pub-id pub-id-type="pmid">11074883</pub-id></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunkari</surname><given-names>VG</given-names></name><name><surname>Lind</surname><given-names>F</given-names></name><name><surname>Botusan</surname><given-names>IR</given-names></name><name><surname>Kashif</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>ZJ</given-names></name><name><surname>Yl&#x000e4;-Herttuala</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hyperbaric oxygen therapy activates hypoxia-inducible factor 1
(HIF-1), which contributes to improved wound healing in diabetic
mice</article-title><source>Wound Repair Regen</source><year>2015</year><volume>23</volume><issue>1</issue><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">25532619</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopf</surname><given-names>HW</given-names></name><name><surname>Holm</surname><given-names>J</given-names></name></person-group><article-title>Hyperoxia and infection</article-title><source>Best Pract Res Clin Anaesthesiol</source><year>2008</year><volume>22</volume><issue>3</issue><fpage>553</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">18831303</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MK</given-names></name><name><surname>Muhvich</surname><given-names>KH</given-names></name><name><surname>Myers</surname><given-names>RA</given-names></name><name><surname>Marzella</surname><given-names>L</given-names></name></person-group><article-title>Hyperoxia prolongs the aminoglycoside-induced postantibiotic
effect in Pseudomonas aeruginosa</article-title><source>Antimicrob Agents Chemother</source><year>1991</year><volume>35</volume><issue>4</issue><fpage>691</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">1906262</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>HM</given-names></name><name><surname>Fridovich</surname><given-names>I</given-names></name></person-group><article-title>Superoxide radical and the oxygen enhancement of the toxicity of
paraquat in Escherichia coli</article-title><source>J Biol Chem</source><year>1978</year><volume>253</volume><issue>22</issue><fpage>8143</fpage><lpage>8148</lpage><pub-id pub-id-type="pmid">213429</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knighton</surname><given-names>DR</given-names></name><name><surname>Silver</surname><given-names>IA</given-names></name><name><surname>Hunt</surname><given-names>TK</given-names></name></person-group><article-title>Regulation of wound-healing angiogenesis-effect of oxygen
gradients and inspired oxygen concentration</article-title><source>Surgery</source><year>1981</year><volume>90</volume><issue>2</issue><fpage>262</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">6166996</pub-id></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mader</surname><given-names>JT</given-names></name><name><surname>Shirtliff</surname><given-names>ME</given-names></name><name><surname>Bergquist</surname><given-names>SC</given-names></name><name><surname>Calhoun</surname><given-names>J</given-names></name></person-group><article-title>Antimicrobial treatment of chronic osteomyelitis</article-title><source>Clin Orthop Relat Res</source><year>1999</year><issue>360</issue><fpage>47</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10101310</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topuz</surname><given-names>K</given-names></name><name><surname>Kutlay</surname><given-names>AM</given-names></name><name><surname>Simsek</surname><given-names>H</given-names></name><name><surname>Colak</surname><given-names>A</given-names></name><name><surname>Kaya</surname><given-names>S</given-names></name><name><surname>Demircan</surname><given-names>MN</given-names></name></person-group><article-title>Effect of hyperbaric oxygen therapy on the duration of treatment
of spinal tuberculosis</article-title><source>J Clin Neurosci</source><year>2009</year><volume>16</volume><issue>12</issue><fpage>1572</fpage><lpage>1577</lpage><pub-id pub-id-type="pmid">19836957</pub-id></element-citation></ref></ref-list></back></article>